PP-008

PP-008 is a preclinical therapeutic candidate under development by Primary Peptides. As of the latest company disclosures, PP-008 is categorized as an "unpublished" program, meaning its specific molecular target, therapeutic modality, and intended clinical indications have not yet been publicly revealed. The developer, Primary Peptides, focuses on the discovery of peptides that block specific protein-protein interactions or induce targeted protein degradation (CHAPTAC technology), primarily for the treatment of neurodegenerative diseases and acute neurological injuries. Consequently, PP-008 is expected to leverage one of these proprietary peptide-based platforms.